You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A Low-SWap Powered Air Purifying Respirator (PAPR)

    SBC: CREARE LLC            Topic: CBD181002

    The proposed low-SWaP PAPR technology improves the convenience, comfort, and protection level for respirators used in low-threat hazardous environments. Creare’s PAPR technology will be applicable to a variety of respiratory protection needs, including emergency escape, laboratory and field work in low-hazard conditions, and some combat and combat support activities. The PAPR will improve user f ...

    SBIR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  2. A Novel Microfludic Device for Drug Toxicity Studies

    SBC: CFD Research Corporation            Topic: CBD10103

    Current drug discovery and development efforts are severely limited by expensive animal trials and oversimplified in vitro models. Results obtained from in vitro models are not predictive of in vivo toxicity owing to significant difference from the in vivo physiological conditions. In this context, we propose to develop and demonstrate a novel microfluidic device that reproduces the physiological ...

    SBIR Phase II 2011 Department of DefenseOffice for Chemical and Biological Defense
  3. 3D Microfluidic Platform for in vitro Hematopoietic Stem Cell (HSC) Culture

    SBC: Physical Optics Corporation            Topic: CBD10103

    Poor drug candidates are often identified late in the drug development process (e.g., in the preclinical and clinical phases) and contribute significantly to the high cost and low yield of drug discovery. As a result, new tools are needed to accelerate the assessment of drug candidate toxicity earlier in the drug development process. To address this Chemical/Bio Defense (CBD) need, Physical Optics ...

    SBIR Phase II 2011 Department of DefenseOffice for Chemical and Biological Defense
  4. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  5. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  6. Microfluidic High-throughput Platform for Determining Kinetic Constants of Enzyme Variants

    SBC: CFD Research Corporation            Topic: CBD10107

    Current high-throughput platforms rely on labeled substrates that produce detectable spectroscopic signals upon reaction for monitoring enzyme catalytic activity. Add to that the high price tag for these instruments, ranging from several hundred thousand to millions of dollars, and there is a clear need for alternate solutions for a label-free, low-cost, high-throughput enzyme screening platform. ...

    SBIR Phase II 2011 Department of DefenseOffice for Chemical and Biological Defense
  7. Miniature Residual Life Indicator

    SBC: Physical Optics Corporation            Topic: CBD10106

    To address the Chemical and Biological Defense (CBD) need for a residual life indicator (RLI) capable of determining the degradation in physical adsorption and reactive capacity arising from battlefield contaminants and exposure to the elements, Physical Optics Corporation (POC) proposes to continue the development of a new Miniature Residual Life Indicator (MRLIN). MRLIN is based on impedance spe ...

    SBIR Phase II 2011 Department of DefenseOffice for Chemical and Biological Defense
  8. Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device

    SBC: Physical Optics Corporation            Topic: CBD10102

    To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to advance development of a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN). This proposed system is based on a new dry powder formulation and a novel design of an inhaler that uses mature components ...

    SBIR Phase II 2011 Department of DefenseOffice for Chemical and Biological Defense
  9. Next Generation Integrated Electrophoretic Nanofluidic Biochip Sensor Platform for the THz Spectroscopic Finger Printing of Biological Species and Age

    SBC: REDONDO OPTICS            Topic: CBD10110

    Redondo Optics Inc. (ROI), proposes to develop and demonstrate a next generation integrated electrophoretic nanofluidic biochip (INTRay-Nanochip) sensor platform for the"label-less"THz spectroscopy finger printing of biological species and agents. In the proposed Phase II of this program, ROI will focus on the engineering development of a manufacturable optical nanolithography technology to enable ...

    SBIR Phase II 2011 Department of DefenseOffice for Chemical and Biological Defense
  10. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable an ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government